Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...

Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

Inovio Pharmaceuticals Inc.-2.00% $72.2M ...

Liberty TripAdvisor Holdings Inc. Series B 0.00% $21.36M Liberty TripAdvisor Holdings Inc. Series A-0.74% $21.32M ...

Globus Medical, a leading musculoskeletal solutions company, has announced its acquisition of Nevro Corp, a global medical ...